Name | Title | Contact Details |
---|
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention of counterfeiting and diversion. We have manufacturing facilities in Hawaii, engineering offices in California, and business development offices in Pennsylvania, Texas and Hong Kong. TruTag`s early technology research was funded in part by the U.S. Army Medical Research division. The company is supported by venture capital firms and strategic corporate investors.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Canadian International Pharmacy Association is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China